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Abstract
Background:  Adiponectin is inversely associated with obesity, insulin resistance, and
atherosclerosis, but little is known about the genetic pathways that regulate the plasma level of this
protein. To find novel genes that influence circulating levels of adiponectin, a genome-wide linkage
scan was performed on plasma adiponectin concentrations before and after 3 weeks of treatment
with fenofibrate (160 mg daily) in the Genetics of Lipid Lowering Drugs and Diet Network
(GOLDN) Study. We studied Caucasian individuals (n = 1121) from 190 families in Utah and
Minnesota. Of these, 859 individuals from 175 families had both baseline and post-fenofibrate
treatment measurements for adiponectin. Plasma adiponectin concentrations were measured with
an ELISA assay. All participants were typed for microsatellite markers included in the Marshfield
Mammalian Genotyping Service marker set 12, which includes 407 markers spaced at
approximately 10 cM regions across the genome. Variance components analysis was used to
estimate heritability and to perform genome-wide scans. Adiponectin was adjusted for age, sex, and
field center. Additional models also included BMI adjustment.
Results: Baseline and post-fenofibrate adiponectin measurements were highly correlated (r =
0.95). Suggestive (LOD > 2) peaks were found on chromosomes 1p35.2 and 3q28 (near the
location of the adiponectin gene).
Conclusion: Two candidate genes, IL22RA1 and IL28RA, lie under the chromosome 1 peak; further
analyses are needed to identify the specific genetic variants in this region that influence circulating
adiponectin concentrations.
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Background
Adiponectin is an adipokine that is inversely related to
both adiposity and many chronic disease risk factors in
several populations. Adiponectin increases insulin sensi-
tivity (i.e., the converse of insulin resistance) when
administered intravenously to rats [1] and has decreased
transcription in the visceral fat of obese as compared to
lean humans [2]. In epidemiologic studies, adiponectin
has been associated cross-sectionally with both waist or
visceral adiposity [3,4] and euglycemic-clamp derived
insulin sensitivity [5,6]. Adiponectin is also hypothesized
to be protective in the pathogenesis of atherosclerosis
[7,8], perhaps by reducing activity of iNOS in the vascular
adventia [9] or by reducing accumulation of lipids in mac-
rophage foam cells [10].
Given the relations of adiponectin with chronic disease
risk factors, there is much interest in learning about the
pathways through which adiponectin itself is regulated.
Several studies have found circulating adiponectin to be
heritable, with heritability estimates ranging from 0.42 to
0.93 [11-15], suggesting that genetic variants play a role in
regulating adiponectin. To find these variants, several
studies have performed whole-genome linkage scans to
determine which areas of the genome may harbor genes
influencing circulating adiponectin concentrations [12-
16]. Unfortunately, likely because of the diverse study
populations used in each of these scans, few significant
linkage results have been replicated across studies.
The Genetics of Lipid Lowering Drugs and Diet Network
(GOLDN) Study is a genetic family study that included a
three-week trial of fenofibrate, a drug that significantly
decreases triglycerides and increases high-density lipopro-
teins without increasing low-density lipoproteins [17].
Although the hypothesized pathway of action for fenofi-
brate does not involve adiponectin, two placebo-control-
led studies have found that short trials of fenofibrate
significantly increased circulating adiponectin [18,19],
while two other short trials of fenofibrate found non-sig-
nificant increases in adiponectin [20,21]. Therefore, in an
attempt to replicate previous linkage results in Caucasians
and to find novel areas of the genome linked to adiponec-
tin, a whole-genome linkage scan of adiponectin meas-
urements at baseline and after three-weeks of fenofibrate
treatment was undertaken in the GOLDN Study.
Methods
Detailed methods can be found in Additional File 1.
The study design and general population for the GOLDN
Study have been previously described [22]. A total of 1121
individuals from 190 families had baseline adiponectin
measurements and were included in the heritability esti-
mates and linkage scans of baseline adiponectin. Of these,
859 individuals from 175 families completed the fenofi-
brate trial and had measurements of post-trial adiponec-
tin and are thus included in analyses of post-trial
adiponectin.
Plasma adiponectin was quantified using an ELISA assay
from R & D Systems (Minneapolis, MN). Comparison of
58 blind replicates embedded in study samples showed
the adiponectin assay had a reliability coefficient of 0.95.
All participants were genotyped using the Marshfield
Mammalian Genotyping Service screening set 12, which
included 407 markers spaced at approximately every 10
cM across the genome. Heritability and linkage analyses
were performed using SOLAR (Sequential Oligogenic
Linkage Analysis Routines) [23]. All models were mini-
mally adjusted for age, age2, sex, and field center. Some
models were additionally adjusted for body mass index
(BMI) in an attempt to reduce the proportion of variance
in adiponectin due to environmental exposures. Two sin-
gle-nucleotide polymorphisms (SNPs, rs17300539 and
rs2241766) in the adiponectin gene (ADIPOQ) were gen-
otyped using a TaqMan assay with allele-specific probes
on the ABI PRISM 7900 HT Sequence Detection System
(Applied Biosystems; Foster City, CA, USA) according to
standardized laboratory protocols [24]. This study was
approved by the centers' institutional review boards, and
all subjects gave informed consent.
Results
Table 1 shows the characteristics of all GOLDN partici-
pants included in these analyses and the subset of partici-
pants with both baseline and post-trial adiponectin
measurements. On average the participants were in their
late 40s, but there was substantial variability in the age of
the study population (ages 18–87) as many families
included two or three generations. On average, the partic-
ipants were overweight (average BMI = 28.3 kg/m2). In the
subset of the study population with baseline and post-
trial adiponectin measurements, there was large variabil-
ity in the change in adiponectin over the three-week trial
of fenofibrate. The mean change in adiponectin was a
decrease of 0.4 μg/ml (median decrease 0.3 μg/ml) with a
standard deviation of 1.4 μg/ml. Changes over the three-
week trial ranged from an increase of 5.8 μg/ml to a
decrease of 6.2 μg/ml. Both transformed and non-trans-
formed measurements of baseline and post-trial adi-
ponectin (see Additional file 1) were highly correlated (r
= 0.95, transformed measurements; r = 0.94, non-trans-
formed measurements). Both baseline and post-trial adi-
ponectin had similar correlations with BMI (r = -0.29 and
r = -0.28, respectively).
Table 2 presents the heritability estimates for both base-
line and post-trial adiponectin. Heritability estimates
increased somewhat after control for BMI. HeritabilityBMC Medical Genetics 2009, 10:39 http://www.biomedcentral.com/1471-2350/10/39
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estimates also increased somewhat for post-trial measure-
ments of adiponectin. However, heritability estimates for
baseline adiponectin, calculated in the subset of individu-
als (n = 859) with post-trial measurements of adiponectin
were nearly identical to those for post-trial adiponectin
(data not shown).
Figure 1 shows the results of the linkage scans for baseline
and post-trial adiponectin for chromosomes 1 and 3.
Linkage scans for baseline adiponectin measured on the
subset of individuals typed for post-trial adiponectin were
nearly identical to the linkage scans for post-trial adi-
ponectin and are thus not shown. Adjustment for BMI
increased the height of the two highest linkage peaks
(chromosomes 1 and 3) for both baseline and post-trial
adiponectin. To assess whether association with two
known polymorphisms in ADIPOQ explained the linkage
on chromosome 3 (the location of ADIPOQ), additional
genome scans were run adjusting for the two polymor-
phisms. Adjustment for ADIPOQ SNP genotypes (mod-
eled additively) attenuated the peak on chromosome 3
only slightly; adjustment for SNP rs17300539 decreased
the peak LOD from 2.04 to 1.91, adjustment for SNP
rs2241766 decreased the peak LOD to 1.94, and adjust-
ment for both SNPs decreased the peak LOD to 1.90.
Table 3 lists all the peaks with LOD scores over 1.5. The
highest LOD score (2.58) was found on chromosome
1p35 for post-trial adiponectin (minimal model + BMI).
The second highest LOD score (2.04) was found on chro-
mosome 3q28 for baseline adiponectin (minimal model
+ BMI). For the peak on chromosome 1p35.2, the -1 LOD
support interval was 50 cM – 64 cM (22.6 Mb-35.0 Mb)
and this region contained 228 genes. Two candidate
genes, interleukin 22 receptor, alpha 1 (IL22RA1, at 24.3
Mb) and interleukin 28 receptor, alpha (IL28RA at 24.4
Mb), were identified. For the peak on chromosome 3q28,
the -1 LOD support interval was 195 cM -217 cM (180.8
Mb – 196.0 Mb) and this region contained 152 genes.
One candidate gene, adiponectin (ADIPOQ at 188.0 Mb),
was identified.
Discussion
Correlations of baseline adiponectin, post-trial 
adiponectin, and measures of adiposity
In the subset of the population (n = 859) where both
baseline and post-trial adiponectin were measured, the
correlation of the two adiponectin measurements was
high (r = 0.95). On average, adiponectin decreased
slightly over the course of the trial. GOLDN is the only
trial we are aware of in which adiponectin concentrations
fell following treatment with fenofibrate. Earlier trials
either reported non-significant increases in adiponectin
Table 1: Characteristics (mean (standard deviation) or percentage) of the GOLDN Study sample
Participants with adiponectin measured at 
baseline (n = 1121)
Participants with adiponectin measured at both 
baseline and post-fenofibrate trial (n = 859)
Age (years) 48.2 (16.3) 48.3 (15.9)
BMI (kg/m2)† 28.3 (5.6) 28.5 (5.5)
Baseline plasma adiponectin (μg/ml)* 7.4 (4.8 – 10.5) 7.2 (4.7 – 10.2)
Post-trial plasma adiponectin (μg/ml)* -- 7.0 (4.5 – 9.9)
Male (%) 48.1 49.6
Center (%)
Minnesota 51.3 49.9
Utah 48.7 51.1
*median (interquartile range)
†measured at baseline
Table 2: Heritability of baseline and post-fenofibrate trial adiponectin
Covariates* Heritability (SE) p-value Proportion of variance due to covariates
Baseline adiponectin
minimal model 0.38 (.06) < .0001 .23
minimal model + BMI 0.44 (.06) < .0001 .29
Post-trial adiponectin
minimal model 0.46 (.07) < .0001 .25
minimal model + BMI 0.55 (.07) < .0001 .30
*Minimal model = age, age2, sex, field center
BMI, body mass index; SE, standard errorBMC Medical Genetics 2009, 10:39 http://www.biomedcentral.com/1471-2350/10/39
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[20,21] or significant increases in adiponectin [18,19].
However, these studies were small (sample sizes ranging
from 10 to 146) and used study populations with hyper-
triglyceridemia, severe obesity, or other chronic diseases.
Given the small mean change in adiponectin and the very
similar results for baseline and post-trial adiponectin her-
itability and linkage analyses when performed in the sub-
set of individuals with both measures, the differences in
analyses of baseline and post-trial adiponectin presented
in this paper may be due to subtle differences in popula-
tion structure between the full sample and subset.
Cross-sectional correlations between adiponectin and
measures of adiposity have been reported in many other
studies. The correlations between adiponectin and BMI in
GOLDN were somewhat low, but still within the range of
correlation values reported previously (r = -0.3 to -0.5)
[4,25].
Heritability analyses
The heritability of adiponectin has been examined previ-
ously in several large family studies [11-15]. The heritabil-
ity estimates in the present study are consistent with
results in other Caucasian study populations; the mini-
mally-adjusted heritability estimate for baseline adi-
ponectin (0.38) is similar to the unadjusted estimate from
a similar sized study of northern Europeans [13] and the
minimally adjusted post-trial adiponectin heritability
estimate (0.46) is similar to an age and sex-adjusted esti-
mate from a study conducted in the Old-Order Amish
(0.55) [15]. Heritability estimates in GOLDN may be
lower than those for some other study populations (par-
Chromosomes 1 and 3 linkage results Figure 1
Chromosomes 1 and 3 linkage results. Chromosomes 1 and 3 linkage results for baseline and post-trial adiponectin. *Min-
imal model includes age, age2, sex, and field center.BMC Medical Genetics 2009, 10:39 http://www.biomedcentral.com/1471-2350/10/39
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ticularly Hispanic or African American study populations)
for a number of reasons. Different or additional genes
may impact circulating adiponectin in these populations,
or different environmental factors (such as obesity) may
influence adiponectin in different populations.
Linkage scans
No areas of (genome-wide) significant linkage were
detected in this analysis. Two areas of suggestive linkage
LOD > 2.0 were detected on chromosomes 1 and 3, and
several areas of modest linkage (2.0 > LOD > 1.5) were
also detected. Several genome-wide linkage scans of adi-
ponectin have been published previously [12-16]. Com-
paring the results of these analyses to the results in the
GOLDN Study reveals that the suggestive peak on chro-
mosome 3q28, and the modest peak on 15q22.32 have
been reported in other studies. In a study of Chinese sib-
lings, a peak was found on chromosome 15 near the loca-
tion of the peak detected in the present study [12]. Peaks
around 200 cM on chromosome 3q have been reported
previously in Hispanic families in the IRAS Family Study
[14], in Northern European Families [13], and in the Old-
Order Amish [15]. The adiponectin gene is located at 202
cM on chromosome 3, and many studies have established
that variants in this gene influence adiponectin concentra-
tions; a meta-analysis of these studies found a significant
association between SNP rs17300539 and circulating adi-
ponectin levels [26]. However, inclusion of this SNP and
SNP rs2241766 (an ADIPOQ SNP shown to significantly
attenuate an adiponectin linkage signal on chromosome
3 in an Amish population [15]) as covariates did not sig-
nificantly attenuate the linkage signal in this study, indi-
cating that other variants in ADIPOQ  (or, potentially,
variants in other genes under the linkage peak) may con-
tribute to this linkage signal. This result mirrors the results
of a linkage analysis in the IRAS Family Study were SNP
rs17300539 was not found to be a major determinant of
the linkage peak found on chromosome 3 [14].
The suggestive peak observed on chromosome 1p35.2
and the modest peaks observed on chromosomes 6p23
and 7p14.2 are novel. The peak observed on chromosome
1p35 in GOLDN has not been reported in other adiponec-
tin linkage scans, but peaks have been found in that loca-
tion in linkage scans of BMI and type 2 diabetes. Both the
Quebec Family Study and a study in the Old-Order Amish
detected significant areas of linkage (p = .05 and p =
.0099) on chromosome 1p35.1 for BMI [27,28]. As the
peak detected on chromosome 1 in GOLDN was not
attenuated after adjustment for BMI (but rather increased
after adjustment for BMI), it is unlikely that the linkage
seen with adiponectin on chromosome 1 in GOLDN is
due to a gene that indirectly affects adiponectin via direct
effects on adiposity. Two possible explanations are that a
pleiotropic gene lies under this peak which influences
both adiposity and adiponectin concentrations through
different pathways, or that two different genes (one influ-
encing adiposity and another influencing adiponectin
concentrations) both lie under this linkage peak. If either
explanation is true, it is not surprising that multiple stud-
ies have also linked this region of the genome to type 2
diabetes [29,30], given the hypothesized relationships
between adiposity, adiponectin, and insulin resistance.
There are several explanations for the novel modest link-
ages observed on chromosomes 6p23 and 7p14.2 in this
study. It is possible that there are some genetic variants
that impact circulating adiponectin in GOLDN, a Cauca-
sian group of families from Utah and Minnesota, but not
in other populations in which linkage scans have been
conducted. It is also possible that some genes impact con-
centrations of circulating adiponectin in all populations,
but that the effect of the genes was not detectable in some
populations due to environmental variation, small effect
sizes, and/or limited statistical power. In GOLDN, partic-
ipants were not permitted to take lipid-lowering drugs or
dietary supplements; this uniformity in the study popula-
Table 3: Maximum LOD scores (over 1.5) for adiponectin
Covariates* Chromosome Distance (cM) LOD p-value Closest marker, location in bp†
Baseline adiponectin
minimal model + BMI 1p35.2 60 1.72 .0024 ATA79C10, 32.8 Mb
minimal model + BMI 3q28 208 2.04 .0011 D3S2398, 187.8 Mb
minimal model 3q28 208 1.75 .0023 D3S2398, 187.8 Mb
minimal model 6p23 26 1.60 .0033 D6S2434, 15.2 Mb
minimal model + BMI 7p14.2 54 1.81 .0019 D7S5817, 32.1 Mb
minimal model 15q22.32 62 1.80 .0020 D15S1507, 42.2 Mb
Post-trial adiponectin
minimal model + BMI 1p35.2 60 2.58 .00028 ATA79C10, 32.8 Mb
minimal model 1p35.2 60 1.52 .0041 ATA79C10, 32.8 Mb
*minimal model = age, age2, sex, field center
†from the Celera map
BMI, body mass index; bp, base pair; LOD, logarithm of the oddsBMC Medical Genetics 2009, 10:39 http://www.biomedcentral.com/1471-2350/10/39
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tion may have reduced environmental variation caused by
these agents which was likely present in other linkage
scans. Finally, given the modest size of the LOD scores for
these linkages, these signals may represent false positive
findings.
Candidate genes
Identifying candidate genes for adiponectin is relatively
difficult as little is known about upstream molecular reg-
ulators of adiponectin. Some studies have suggested that
adiponectin production and secretion is regulated in vivo
and in vitro by cytokines and their receptors such as IL-6
and TNF-α [31]. Another study has suggested that free
fatty acids also acutely regulate adiponectin concentra-
tions [32]. Finally, the cross-sectional association between
adiponectin and adiposity is well established, so genes
under the suggestive LOD peaks known to be involved
with these three pathways were identified as possible can-
didate genes.
Two cytokine receptor genes were identified as candidate
genes on chromosome 1p35. IL22RA1 encodes a portion
of the receptor for interleukin 22. Interleukin 22 is a
cytokine involved in the acute-phase inflammatory
response. The second gene, IL28RA, also encodes a por-
tion of a cytokine receptor; IL28RA is believed to be a sub-
unit in the receptors for interleukin 28A, interleukin 28B,
and interleukin 29. If interleukin 22, 28A, 28B, or 29 reg-
ulate adiponectin, then variations in genes involved in the
receptors for these cytokines may impact circulating con-
centrations of adiponectin. The most likely explanation
for the linkage peak observed on 3q28 is the adiponectin
gene itself, as it has been shown that variation in this gene
influences circulating concentrations of adiponectin in
many populations. No other candidate genes were found
under the peak on 3q28.
Strengths and limitations
A primary strength of this study was that the study popu-
lation likely had less variability in environmental expo-
sures than other observational studies, as no individuals
participating in the trial took lipid-lowering drugs or cer-
tain dietary supplements during the study period.
Homogenous environmental exposures reduce the impact
of gene by environment interactions which can mask link-
age signals.
There were limitations to this study. The results may not
be widely generalizable because of the homogeneity of
the study population. Additionally, no household infor-
mation was collected in the GOLDN Study which pre-
vented the use of a household (shared environment)
matrix in heritability and linkage analyses. As a result, her-
itability may have been overestimated if variance due to
common environment was mistakenly attributed to vari-
ance due to additive genetic effects.
Conclusion
This study performed whole-genome linkage scans for cir-
culating adiponectin before and after a three-week trial of
fenofibrate. There was a very high tracking correlation for
adiponectin before and after the fenofibrate trial, and it
was hypothesized that any meaningful difference in the
heritabilities or linkage scans for the baseline and post-
fenofibrate measurements of adiponectin was due to dif-
ferences between the baseline sample and sub-sample that
completed the trial of fenofibrate. Adiponectin was found
to be moderately heritable, and the heritability increased
after adjustment for BMI. No areas of significant (LOD >
3) linkage were discovered, but there were two suggestive
(LOD > 2) peaks on chromosomes 1p35.2, and 3q28. The
peak on chromosome 1 corroborates areas of significant
linkage for BMI and type 2 diabetes mellitus. The peak on
chromosome 3 contains ADIPOQ.
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